Skip to main content
Profile picture for Jack Cush, MD

Jack Cush, MD

Dr. Cush is the Executive Editor of RheumNow.com and also Co-Edits the online textbook RheumaKnowledgy.com. 
  
Dr. Cush's interests include medical education, novel drug development, rheumatoid arthritis, spondyloarthritis, drug safety, and Still's disease/autoinflammatory syndromes. He has published over 140 articles and 2 books in rheumatology.
 
He can be followed on twitter: @RheumNow

Articles By Jack Cush, MD

boy.girl_.jpg (keep)

Half of US Women are Overweight during Pregnancy

Obesity is associated with adverse outcomes in pregnancy, especially with higher rates of infertility and miscarriage. 

Read Article
stemcells.jpg

The Unproven Use of Stem Cell Therapy in OA of the Knee

Regenerative medicine and the use of bone marrow stromal cells (or mesenchymal stem cells - MSC) is controversial in many areas of medicine, including osteoarthritis. MSC use is at a very early stage in orthopedic research, but has been investigated in osteoarthritis of the kn

Read Article
beer-drinker.png

Obesity Drives Rheumatoid Arthritis

Systematic review of the literature examined whether obesity is associated with a higher risk of rheumatoid arthritis (citation source http://url.ie/z1y6) and found that obese individuals (BMI > 30) are at 

Read Article
across%20table.jpg

Across the Table: Cush & Schwartzman on Uveitis

In this edition of “Across the Table”, Drs. Cush and Schwartman discuss uveitis. Our expert, Dr. Sergio Schwartzman offers up his approach to diagnosis and management.

Read Article
pillpack.jpg

TNF inhibitors in Early Axial SpA Spares NSAID Use

In a 2 year follow-up of the DESIR cohort of patients with early inflammatory back pain (627 patients), TNF inhibitor use was associated with a significantly greater decrease in the median NSAID intake (from 54.9 to 1.9 in TNFi pts versus from 41.9 to 22.3 in non-TNFi pts, p0.05).

Read Article
vials.jpg

Ustekinumab Efficacy in Psoriatic Arthritis: 2 Year SUMMIT Trial Results

615 adults with active PsA were randomized to ustekinumab (45mg group or 90mg group) or placebo with crossover at 24 weeks.

Read Article

The Obfuscation of Fibromyalgia

What is going on in the wide and wacky world of pain and fatigue? What use to be called fibromyalgia is being reclassified as myalgic encephalomyelitis (ME/CFS) or systemic exertion intolerance disease. Although fibromyalgia has many faces, it does not deserve many names.

Read Article
IMG_1538.JPG

Ustekinumab Bests TNF Inhibitors for Biologic Survival in Psoriasis

Using drug survival as a global measure of a drug's effectiveness, safety and tolerability, UK investigators used a national pharmacovigilance cohort (British Association of Dermatologists Biologic Interventions Register) to compare survival rates of the first biologic used in 3,523 biologic-naiv

Read Article
lab%20tests.jpeg

Utility of Drug Levels and Anti-Drug Antibodies When Starting TNF inhibitors

A prospective cohort of 331 patients tested for anti-adalimumab (n=160) and anti-etanercept (n-171) antibodies after initiation of their TNF inhibitor therapy.

Read Article
IPF.JPG

Microscopic Polyangiitis Associated with Pulmonary Fibrosis

Microscopic polyangiitis (MPA) is one of several vasculitides that affects the lung.  Its most common pulmonary complication is diffuse alveolar haemorrhage, which carries a significant morbid risk.

Read Article
×